Blog
RSS FeedPosted by Michael Wonder on 09 Sep 2020
Another appraisal terminated by NICE
9 September 2020 - That makes it 9 terminated appraisals so this calendar year. ...
Posted by Michael Wonder on 09 Sep 2020
Alimera Sciences obtains reimbursement approval for Iluvien use in non-infectious posterior uveitis in Scotland
8 September 2020 - Alimera Sciences announces that the Scottish Medicines Consortium, after completing its assessment and review, has accepted (per ...
Posted by Michael Wonder on 09 Sep 2020
PHARMAC opens consultation to address New Zealand’s biggest health issue
9 September 2020 - Proposal to list type 2 diabetes medicine Jardiance. ...
Posted by Michael Wonder on 09 Sep 2020
Ascendis Pharma submits marketing authorisation application to the EMA for TransCon hGH for the treatment of paediatric growth hormone deficiency
8 September 2020 - Ascendis Pharma announced today the submission of a marketing authorisation application to the EMA seeking approval for ...
Posted by Michael Wonder on 09 Sep 2020
PHARMAC seeking views on new type 2 diabetes medicines
9 September 2020 - PHARMAC is looking at funding two new medicines with substantial health benefits for up to 50,000 ...
Posted by Michael Wonder on 08 Sep 2020
BeyondSpring receives breakthrough therapy designations from both U.S. FDA and China NMPA for plinabulin in chemotherapy-induced neutropenia indication
8 September 2020 - Among the first three innovative drugs to receive breakthrough therapy designations in China. ...
Posted by Michael Wonder on 08 Sep 2020
U.S. FDA approves Athena Bioscience's new drug application for Qdolo (tramadol hydrochloride) oral solution
8 September 2020 - FDA approved Qdolo (tramadol hydrochloride), an oral liquid, accommodates dosing flexibility, precise titration. ...
Posted by Michael Wonder on 08 Sep 2020
NICE releases initial guidance for another indication for lenalidomide
8 September 2020 - This time, it is for use as maintenance treatment after autologous stem cell transplantation for patients ...
Posted by Michael Wonder on 08 Sep 2020
South Korea to shorten licensing review period new drugs on rare diseases by 25 days
8 September 2020 - Korean health regulators will shorten licensing review period from 115 days to 90 days for investigational ...
Posted by Michael Wonder on 08 Sep 2020
Singapore's Agency for Care Effectiveness publishes another tranche of drug guidances
1 September 2020 - Plain English summaries are also available. ...
Posted by Michael Wonder on 08 Sep 2020
SMC accepts three new health technologies for interim use
7 September 2020 - In what appears to be a new process, the SMC has accepted three new technologies for ...
Posted by Michael Wonder on 08 Sep 2020
Nurse specialists say plight of severely ill bowel disease patients in NZ is bitterly unfair
8 September 2020 - Senior Clinical Nurse specialists caring for some of New Zealand’s sickest bowel disease patients say the ...
Posted by Michael Wonder on 08 Sep 2020
ICR welcomes approval of immunotherapy for head and neck cancer in Scotland but warns of ‘home nations lottery’
7 September 2020 - The Institute of Cancer Research, London, has welcomed the approval by the Scottish Medicines Consortium of ...
Posted by Michael Wonder on 08 Sep 2020
Janssen announces European Commission decision for expanded use of Imbruvica (ibrutinib) in combination with rituximab for previously untreated patients with chronic lymphocytic leukaemia
7 September 2020 - Patients who were new to chronic lymphocytic leukaemia treatment lived longer without disease progression with the Imbruvica ...
Posted by Michael Wonder on 07 Sep 2020
Four new medicines accepted by SMC through an expedited approach
7 September 2020 - Medicines accepted to minimise delay in patient access following the early phase of the COVID-19 pandemic. ...